![](https://www.canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBbzRDIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--4c56c75c76d167ab2d2ad3cbf175a59f773dbed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/antiva.png)
Antiva Biosciences
Antiva is developing a topical HPV anti-viral treatment for cervical pre-cancerous lesions.
Website
www.antivabio.comPartner
Wende HuttonInvestment
Series B
Antiva is developing a topical HPV anti-viral treatment for cervical pre-cancerous lesions.
Series B